Physician profile
Nagesh Krish
NPI 1710918115
$46,234.30
in general payments reported to CMS, 2019-2025
97 companies · $8,398 in 2025
The $8,398 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,523 · 2020: $3,229 · 2021: $7,008 · 2022: $7,856 · 2023: $7,577 · 2024: $7,643 · 2025: $8,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $140 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,434.87 |
| Education | $140.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,296.29 | 2021-2025 | |
| Emd Serono, INC. | $3,596.88 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $3,048.03 | 2019-2025 | Vumerity, Tysabri, Qalsody |
| Lundbeck LLC | $1,945.75 | 2020-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $1,504.34 | 2020-2025 | Crexont, Rytary, Ongentys |
| Sk Life Science, INC. | $1,440.00 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $1,401.78 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $1,357.41 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,279.43 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $1,209.48 | 2020-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $1,178.37 | 2019-2025 | |
| Axsome Therapeutics, INC. | $1,174.14 | 2023-2025 | Sunosi, Symbravo, Auvelity |
| Teva Pharmaceuticals USA, INC. | $1,070.84 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $1,052.36 | 2019-2025 | Apokyn, Apokyn, Xadago |
| Medtronic, INC. | $905.27 | 2021-2025 | Visualase, Percept PC Brainsense |
Show all 97 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagesh Krish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.